public BRAFV600EKDetectedMetastaticMelanomaResult()
{
YellowstonePathology.Business.Test.IndicationMetastaticMelanoma indication = new IndicationMetastaticMelanoma();
this.m_Indication = indication.IndicationCode;
this.m_IndicationComment = indication.Description;
this.m_Interpretation = "The BRAF gene, a member of the RAS-RAF-MEK-MAPK pathway that drives tumor growth and progression, " +
"has been found to play a pivotal role in melanoma oncogenesis. Recent studies have shown that approximately 50% of melanomas harbor a point mutation in codon " +
"600 of the BRAF gene, resulting in the substitution of glutamic acid for valine in the encoded protein. This alteration results in constitutive activation of " +
"the BRAF protein kinase, and thus, the RAS-RAF-MEK-MAPK pathway. Testing for the BRAF V600E/K mutation in metastatic melanomas is useful for guiding therapy.\r\n\r\n" +
"Melanomas with the V600E/K mutation have been shown to respond to the new BRAF inhibitors. A 107-base product indicative of a BRAF V600E/K mutation was detected " +
"by high resolution capillary electrophoresis. Therefore this patient may benefit from the new BRAF inhibitors.";
this.m_Comment = "The patient may benefit from the use of the new BRAF inhibitors.";
this.m_References = BRAFV600EKResult.MetastaticMelanomaReference;
}
public BRAFV600EKDetectedMetastaticMelanomaResult()
{
YellowstonePathology.Business.Test.IndicationMetastaticMelanoma indication = new IndicationMetastaticMelanoma();
this.m_Indication = indication.IndicationCode;
this.m_IndicationComment = indication.Description;
this.m_Interpretation = "The BRAF gene, a member of the RAS-RAF-MEK-MAPK pathway that drives tumor growth and progression, " +
"has been found to play a pivotal role in melanoma oncogenesis. Recent studies have shown that approximately 50% of melanomas harbor a point mutation in codon " +
"600 of the BRAF gene, resulting in the substitution of glutamic acid for valine in the encoded protein. This alteration results in constitutive activation of " +
"the BRAF protein kinase, and thus, the RAS-RAF-MEK-MAPK pathway. Testing for the BRAF V600E/K mutation in metastatic melanomas is useful for guiding therapy.\r\n\r\n" +
"Melanomas with the V600E/K mutation have been shown to respond to the new BRAF inhibitors. A 107-base product indicative of a BRAF V600E/K mutation was detected " +
"by high resolution capillary electrophoresis. Therefore this patient may benefit from the new BRAF inhibitors.";
this.m_Comment = "The patient may benefit from the use of the new BRAF inhibitors.";
this.m_References = BRAFV600EKResult.MetastaticMelanomaReference;
}
public BRAFV600EKNotDetectedMetastaticMelanomaResult()
{
YellowstonePathology.Business.Test.IndicationMetastaticMelanoma indication = new IndicationMetastaticMelanoma();
this.m_Indication = indication.IndicationCode;
this.m_IndicationComment = "Note: False negatives may occur if the sample does not contain a sufficient quantity of tumor DNA. If " +
"this test was performed on a small/scant sample and subsequent surgical excision confirms the presence of papillary thyroid carcinoma, retesting on the surgical " +
"specimen is recommended.";
this.m_Interpretation = "The BRAF gene, a member of the RAS-RAF-MEK-MAPK pathway that drives tumor growth and progression, has " +
"been found to play a pivotal role in melanoma oncogenesis. Recent studies have shown that approximately 50% of melanomas harbor a point mutation in codon 600 of the " +
"BRAF gene, resulting in the substitution of glutamic acid for valine in the encoded protein. This alteration results in constitutive activation of the BRAF protein " +
"kinase, and thus, the RAS-RAF-MEK-MAPK pathway. Testing for the BRAF V600E/K mutation in metastatic melanomas is useful for guiding therapy.\r\n\r\n" +
"Melanomas with the V600E/K mutation have been shown to respond to the new BRAF inhibitors. A 107-base product indicative of a BRAF V600E/K mutation was NOT detected " +
"by high resolution capillary electrophoresis. Therefore this tumor is not likely to respond to the new BRAF inhibitors.";
this.m_Comment = "The patient will likely not benefit from the use of the new BRAF inhibitors.";
this.m_References = BRAFV600EKResult.MetastaticMelanomaReference;
}
public BRAFV600EKNotDetectedMetastaticMelanomaResult()
{
YellowstonePathology.Business.Test.IndicationMetastaticMelanoma indication = new IndicationMetastaticMelanoma();
this.m_Indication = indication.IndicationCode;
this.m_IndicationComment = "Note: False negatives may occur if the sample does not contain a sufficient quantity of tumor DNA. If " +
"this test was performed on a small/scant sample and subsequent surgical excision confirms the presence of papillary thyroid carcinoma, retesting on the surgical " +
"specimen is recommended.";
this.m_Interpretation = "The BRAF gene, a member of the RAS-RAF-MEK-MAPK pathway that drives tumor growth and progression, has " +
"been found to play a pivotal role in melanoma oncogenesis. Recent studies have shown that approximately 50% of melanomas harbor a point mutation in codon 600 of the " +
"BRAF gene, resulting in the substitution of glutamic acid for valine in the encoded protein. This alteration results in constitutive activation of the BRAF protein " +
"kinase, and thus, the RAS-RAF-MEK-MAPK pathway. Testing for the BRAF V600E/K mutation in metastatic melanomas is useful for guiding therapy.\r\n\r\n" +
"Melanomas with the V600E/K mutation have been shown to respond to the new BRAF inhibitors. A 107-base product indicative of a BRAF V600E/K mutation was NOT detected " +
"by high resolution capillary electrophoresis. Therefore this tumor is not likely to respond to the new BRAF inhibitors.";
this.m_Comment = "The patient will likely not benefit from the use of the new BRAF inhibitors.";
this.m_References = BRAFV600EKResult.MetastaticMelanomaReference;
}
